Managing Assessments and Expectations: Patient Responses Following Therapy With Efinaconazole Topical Solution, 10%

REFERENCES

1. Seebacher C, Brasch J, Abeck D, et al. Onychomycosis. Mycoses. 2007;50:321-327.
2. Gupta AK, Simpson FC. New therapeutic options for onychomycosis: an update Expert Opin Pharmacother. 2012;13(8):1131-1142.
3. Gupta AK, Daniel CR: Onychomycosis: Strategies to Reduce Treatment Failure and Recurrence. Cutis. 1998;62:189-191.
4. Gupta AK, Daniel CR: Factors that may affect the response of Onychoymosis to oral antifungal therapy. Australas J Dermatol. 1998;39(4):222-224.
5. Daniel CR, Piracinni BM, Tosti A: The Disappearing Nail Bed: A possible outcome of Onycholysis. Cutis 2005;76:325-327.
6. Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol. 1997;36:754-756.
7. Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol. 1998;38 (5 Pt 1):702–704.
8. Yaemsirl S, Hou N, Slining MM, et al. Growth rate of human fingernails and toenails in healthy American young adults. J Eur Acad Dermatol Venereol. 2010;24(4):420-423.
9. Hu Y, Yang LJ, Wei L, et al. Study on the compliance and safety of the oral antifungal agents for the treatment of onychomycosis. Zhonghua Liu Xing Bing Xue Za Zhi. 2005;26(12):988-991.
10. Zhou ZL, Zhang JP, Wang XM, et al. Compliance of the patients and related influential factors on the topical antifungal treatment of onychomycosis. Zhonghua Liu Xing Bing Xue Za Zhi. 2011;32(7):720-723.
11. Effendy I, Kolczak H, Friederich HC. Noncompliance relevant variables in patients with onychomycosis. Wien Med Wochenschr. 1989;139(15-16):356-359.
12. Szepietowski JC, Reich A; for the National Quality of Life in Dermatology Group. Stigmatisation in onychomycosis patients: a population-based study. Mycoses 2008;52 (4):343–349.
13. Szepietowski JC, Reich A, Wozniak M, et al. Evaluation of quality of life in patients with onychomycosis using the Polish version of Dermatology Life Quality Index, Mikol Lek. 2006;13:193–198.
14. Belyayeva E, Gregoriou S, Chalikias J, et al. The impact of nail disorders on quality of life. Eur J Dermatol. 2013;23(3):336-371.
15. Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase 3 multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600-608.
16. Scher RK, Tavakkol A, Sigurgeirsson B et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol. 2007;56:939–944.
17. Elewski BE. A full ''cure'' for onychomycosis is not always possible. Arch Dermatol 1999;135:852–853.
18. Gupta AK, Elewski BE, Sugarman JL, et al. The efficacy and safety of efinaconazole 10% solution for the treatment of mild to moderate onychomycosis: a pooled anaylsis of two phase 3 randomized trials. J Drugs Dermatol. 2014;13(7):815-820.
19. Rich P. Efinaconazole topical solution, 10%: the benefit of treating onychomycosis early. J Drugs Dermatol 2015;14(1):58-62.

AUTHOR CORRESPONDENCE